Phibro Animal Health (NASDAQ:PAHC) Releases FY 2027 Earnings Guidance

Key Points

• Phibro Animal Health issued FY 2027 guidance for EPS of $3.41–$3.59 and revenue of approximately $1.6 billion, both above analyst consensus estimates of $3.34 EPS and $1.5 billion in revenue.
• The company’s latest quarter included adjusted EPS of $0.53, below the $0.71 analyst estimate, while revenue of $396.75 million exceeded expectations. Shares recently traded near $36.09, well below their 52-week high of $60.08.
• Analysts maintain an average “Hold” rating with a $42.50 price target, while Phibro declared a quarterly dividend of $0.12 per share, equivalent to a 1.3% annualized yield.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) issued an update on its FY 2027 earnings guidance on Wednesday. The company provided earnings per share guidance of 3.410-3.590 for the period, compared to the consensus earnings per share estimate of 3.340. The company issued revenue guidance of $1.6 billion-$1.6 billion, compared to the consensus revenue estimate of $1.5 billion.

Phibro Animal Health Stock Performance

Shares of PAHC traded up $0.16 on Wednesday, reaching $36.09. 287,583 shares of the company's stock traded hands, compared to its average volume of 295,650. The stock has a market cap of $1.46 billion, a PE ratio of 15.49, a PEG ratio of 0.50 and a beta of 0.46. Phibro Animal Health has a 52-week low of $28.25 and a 52-week high of $60.08. The company has a current ratio of 3.17, a quick ratio of 1.26 and a debt-to-equity ratio of 1.97. The stock's 50 day simple moving average is $33.84 and its two-hundred day simple moving average is $42.54.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last posted its quarterly earnings data on Wednesday, August 26th. The company reported $0.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.71 by ($0.18). Phibro Animal Health had a return on equity of 37.14% and a net margin of 6.35%.The company had revenue of $396.75 million for the quarter, compared to analysts' expectations of $381.18 million. Phibro Animal Health has set its FY 2027 guidance at 3.410-3.590 EPS. On average, analysts forecast that Phibro Animal Health will post 3.08 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Wednesday, September 2nd will be issued a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, September 2nd. This represents a $0.48 annualized dividend and a yield of 1.3%. Phibro Animal Health's dividend payout ratio is 20.60%.

Analysts Set New Price Targets

Several research firms recently commented on PAHC. Zacks Research downgraded shares of Phibro Animal Health from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 21st. Citigroup dropped their price objective on shares of Phibro Animal Health from $62.00 to $44.00 and set a "neutral" rating for the company in a report on Thursday, May 14th. Wall Street Zen lowered shares of Phibro Animal Health from a "strong-buy" rating to a "buy" rating in a research report on Saturday, May 9th. Finally, Weiss Ratings cut shares of Phibro Animal Health from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Monday, June 15th. One investment analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Phibro Animal Health currently has an average rating of "Hold" and an average price target of $42.50.

Institutional Investors Weigh In On Phibro Animal Health

A number of hedge funds have recently made changes to their positions in the company. Millennium Management LLC raised its holdings in shares of Phibro Animal Health by 4,227.1% during the 4th quarter. Millennium Management LLC now owns 641,313 shares of the company's stock worth $23,959,000 after acquiring an additional 626,492 shares in the last quarter. Lazard Asset Management LLC raised its stake in Phibro Animal Health by 3,392.3% during the second quarter. Lazard Asset Management LLC now owns 92,441 shares of the company's stock valued at $2,360,000 after purchasing an additional 89,794 shares in the last quarter. Barclays PLC raised its stake in Phibro Animal Health by 47.4% during the third quarter. Barclays PLC now owns 269,568 shares of the company's stock valued at $10,907,000 after purchasing an additional 86,719 shares in the last quarter. Federated Hermes Inc. lifted its position in Phibro Animal Health by 320.2% during the fourth quarter. Federated Hermes Inc. now owns 96,911 shares of the company's stock valued at $3,621,000 after purchasing an additional 73,849 shares during the last quarter. Finally, Qube Research & Technologies Ltd lifted its position in Phibro Animal Health by 40.2% during the third quarter. Qube Research & Technologies Ltd now owns 255,353 shares of the company's stock valued at $10,332,000 after purchasing an additional 73,231 shares during the last quarter. 99.34% of the stock is currently owned by hedge funds and other institutional investors.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation NASDAQ: PAHC is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source